[1] 陈琪,陆建,郭金和.晚期非小细胞肺癌免疫治疗研究进展[J].东南大学学报(医学版),2021,40(4):536-541.
[2] 秦侨西,王稼劲,王红.ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析[J].中国肺癌杂志,2020,23(9):772-791.
[3] SHI Y,FANG J,ZHOU C,et al.Immune checkpoint inhibitor-related adverse events in lung cancer:real-world incidence and management practices of 1905 patients in China[J].Thorac Cancer,2022,13(3):412-422.
[4] 崔少华,葛晓晓,李向阳.免疫相关不良事件在肺癌中发生和结局的真实世界研究[J].中国肺癌杂志,2023,26(4):257-264.
[5] SURESH K,VOONG K R,SHANKAR B,et al.Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy:incidence and risk factors[J].J Thorac Oncol,2018,13(12):1930-1939.
[6] PETRELLI F,GRIZZI G,GHIDINI M,et al.Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors:a systematic review and Meta-analysis[J].J Immunother,2020,43(1):1-7.
[7] TIU B C,ZUBIRI L,IHEKE J,et al.Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors:a multi-institutional cohort study[J].J Immunother Cancer,2022,10(6):e004670.
[8] WILLIAM T A,CAROLINA A,SHRUTI S,et al.Immune checkpoint inhibitor-related pneumonitis in lung cancer:real-world incidence,risk factors,and management practices across six health care centers in north carolina[J].Chest,2021,160(2):731-742.
[9] LI M,SPAKOWICZ D,ZHAO S,et al.Brief report:inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer[J].Cancer Immunol Immunother,2020,69(11):2403-2408.
[10] WANG H,ZHOU F,ZHAO C,et al.Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy[J].Front Immunol,2022,13:840313.
[11] XUGUANG C,KHADIJA S,ERICA N,et al.Radiation versus immune checkpoint inhibitor associated pneumonitis:distinct radiologic morphologies[J].Oncologist,2021,26(10):e1822-e1832.
[12] 曾天星,赵明栋,夏伟.免疫检查点抑制剂相关肺炎的危险因素及机制[J].临床肺科杂志,2023,28(3):423-426.
[13] 陈秀兰,吴旭,李佳旻,等.肺癌患者免疫检查点抑制剂相关性肺炎的临床分析[J].中国呼吸与危重监护杂志,2021,20(9):637-642.
[14] ROSE L M,DEBERG H A,VISHNU P,et al.Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors[J].Front Oncol,2020,10:570752.
[15] SCHOENFELD A J,ARBOUR K C,RIZVI H,et al.Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib[J].Ann Oncol,2019,30(5):839-844.
[16] TAYLOR J,GANDHI A,GRAY E,et al.Checkpoint inhibitor immune-related adverse events:a focused review on autoantibodies and B cells as biomarkers,advancements and future possibilities[J].Front Immunol,2022,13:991433.
[17] BALASUBRAMANIAN A,ONGGO J,GUNJUR A,et al.Immune checkpoint inhibition with chemoradiotherapy in stage III non-small-cell lung cancer:a systematic review and Meta-analysis of safety results[J].Clin Lung Cancer,2021,22(2):74-82.
[18] SU Q,ZHU E C,WU J B,et al.Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors:a systematic review and Meta-analysis[J].Front Immunol,2019,10:108.
[19] GAO J,ZHANG P,TANG M,et al.Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer:a prospective real-world analysis[J].J Cancer Res Clin Oncol,2023,149(11):8993-9006.
[20] MICHAILIDOU D,KHAKI A R,MORELLI M P,et al.Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors[J].Sci Rep,2021,11(1):9029.
[21] CHU X,ZHAO J,ZHOU J,et al.Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J].Lung Cancer,2020,150:76-82.
[22] HARAGUCHI M,NAKAO Y,NARITA S,et al.Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors[J].Cancer Med,2023,12(9):10636-10646.
[23] LIN X,DENG H,YANG Y,et al.Peripheral blood biomarkers for early diagnosis,severity,and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J].Front Oncol,2021,11:698832.
[24] LI Y,JIA X,DU Y,et al.Eosinophil as a biomarker for diagnosis,prediction,and prognosis evaluation of severe checkpoint inhibitor pneumonitis[J].Front Oncol,2022,12:827199.
[25] 宋娟丽,王志芬,冀青青,等.非小细胞肺癌患者抗PD-L1治疗前后NK细胞动态变化与治疗反应性的相关性[J].东南大学学报(医学版),2023,42(5):666-672.
[26] LIU W,LIU Y,MA F,et al.Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors[J].Cancer Manag Res,2021,13:765-771.
[27] FUJIMOTO A,TOYOKAWA G,KOUTAKE Y,et al.Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer[J].Thorac Cancer,2021,12(15):2198-2204.
[28] MATSUKANE R,WATANABE H,MINAMI H,et al.Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset,severity,and subsequent prognosis of immune related adverse events[J].Sci Rep,2021,11(1):1324.
[29] CHAO Y,ZHOU J,HSU S,et al.Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer[J].Transl Lung Cancer Res,2022,11(2):295-306.
[30] COSTANTINI A,JULIE C,DUMENIL C,et al.Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab[J].Oncoimmunology,2018,7(8):e1452581.
[31] HIRASHIMA T,KANAI T,SUZUKI H,et al.The levels of interferon-gamma release as a biomarker for non-small-cell lung cancer patients receiving immune checkpoint inhibitors[J].Anticancer Res,2019,39(11):6231-6240.
[32] LIU X,HAO N,YANG S,et al.Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients[J].Front Oncol,2023,13:1145143.
[33] MADJAR K,MOHINDRA R,DURÁN-PACHECO G,et al.Baseline risk factors associated with immune related adverse events and atezolizumab[J].Front Oncol,2023,13:1138305.
[34] LES I,MARTÍNEZ M,NARRO A,et al.Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies[J].Ann Med,2021,53(1):762-769.
[35] TAHIR S A,GAO J,MIURA Y,et al.Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities[J].Proc Natl Acad Sci U S A,2019,116(44):22246-22251.
[36] BERNER F,BOMZE D,LICHTENSTEIGER C,et al.Autoreactive napsin a-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade[J].Sci Immunol,2022,7(75):eabn9644.
[37] SURESH K,NAIDOO J,ZHONG Q,et al.The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis[J].J Clin Invest,2019,129(10):4305-4315.
[38] SUGANO T,SEIKE M,SAITO Y,et al.Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer[J].Thorac Cancer,2020,11(4):1052-1060.
[39] WANG Y N,LOU D F,LI D Y,et al.Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J].Oncol Lett,2020,20(1):611-622.
[40] CORREALE P,SALADINO R E,GIANNARELLI D,et al.HLA Expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis[J].Cells,2020,9(9):1964.
[41] ABED A,LAW N,CALAPRE L,et al.Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy[J].Eur J Cancer,2022,172:98-106.
[42] XIN Z,YOU L,NA F,et al.Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors[J].Eur J Cancer,2023,184:124-136.
[43] STEPHEN B,HAJJAR J,SARDA S,et al.T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy[J].J Immunother Cancer,2023,11(8):e007236.
[44] MARSCHNER D,FALK M,JAVORNICZKY N R,et al.MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors[J].JCI Insight,2020,5(6):e132334.
[45] YANG L,BOLDIN M P,YU Y,et al.miR-146a controls the resolution of T cell responses in mice[J].J Exp Med,2012,209(9):1655-1670.
[46] BOLDIN M P,TAGANOV K D,RAO D S,et al.miR-146a is a significant brake on autoimmunity,myeloproliferation,and cancer in mice[J].J Exp Med,2011,208(6):1189-1201.
[47] WEIDHAAS J,MARCO N,SCHEFFLER A W,et al.Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy[J].J Immunother Cancer,2022,10(2):e003625.
[48] GUO M,LU Z,XIONG Y.Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes[J].Front Oncol,2022,12:1048127.
[49] JING Y,LIU J,YE Y,et al.Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy[J].Nat Commun,2020,11(1):4946.
[50] LIN X,CHEN X,LONG X,et al.New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors[J].Respir Res,2023,24(1):64.
[51] JIA X,ZHANG Y,LIANG T,et al.Comprehensive nomogram models for predicting checkpoint inhibitor pneumonitis[J].Am J Cancer Res,2023,13(6):2681-2701. |
